# PSMAcTION (NCT06780670)

> Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06780670
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Prostate Cancer
- Interventions: Investigators choice of SoC; AAA817; AAA817; AAA817
- Enrollment: 443
- Primary outcome: Biochemical response rate (Phase II)
- Primary outcome: Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II
- Primary outcome: Tolerability of the proposed dose of AAA817- Phase II
- Primary outcome: Radiographic progression-free survival (rPFS)- Phase III
- Primary outcome: Overall survival (OS)- Phase III

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=psmaction-nct06780670

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06780670", "email": "<work email>"}; the inbox owner confirms by the emailed link.